Olatunji Alese, MD

home / authors / olatunji-alese-md

Articles

Richard Finn, MD;Olatunji Alese, MD;Daneng Li, MD;Anthony El-Khoueiry, MD;Masatoshi Kudo, MD, PhD;Steven Chan, MD

October 25th 2024

Panelists discuss the findings from the LEAP-012 study, which explores the efficacy of transarterial chemoembolization combined with lenvatinib and pembrolizumab in patients with Child-Pugh class A disease and intermediate-stage hepatocellular carcinoma.

LEAP-012 Study Results

Richard Finn, MD;Olatunji Alese, MD;Daneng Li, MD;Anthony El-Khoueiry, MD;Masatoshi Kudo, MD, PhD;Steven Chan, MD

October 25th 2024

Panelists discuss the results of the LEAP-012 study, highlighting the efficacy of transarterial chemoembolization combined with lenvatinib and pembrolizumab in patients with intermediate-stage hepatocellular carcinoma and Child-Pugh class A disease.

Use of monotherapy (IO or TKI) or localized treatment in First Line

Richard Finn, MD;Olatunji Alese, MD;Daneng Li, MD;Anthony El-Khoueiry, MD;Masatoshi Kudo, MD, PhD;Steven Chan, MD

October 18th 2024

Panelists discuss the circumstances under which monotherapy with a tyrosine kinase inhibitor or immunotherapy would be preferred in the treatment of unresectable hepatocellular carcinoma.

Current Treatment in First Line – IO + TKI or IO + IO

Richard Finn, MD;Olatunji Alese, MD;Daneng Li, MD;Anthony El-Khoueiry, MD;Masatoshi Kudo, MD, PhD;Steven Chan, MD

October 18th 2024

Panelists discuss current treatment options for unresectable hepatocellular carcinoma, including atezolizumab plus bevacizumab, durvalumab plus tremelimumab, and transarterial chemoembolization, along with the factors influencing treatment decisions.

Treatment Decisions Based on BLCL Stage

Richard Finn, MD;Olatunji Alese, MD;Daneng Li, MD;Anthony El-Khoueiry, MD;Masatoshi Kudo, MD, PhD;Steven Chan, MD

October 7th 2024

Current Treatment Landscape – difference between unresectable (uHCC) and metastatic (mHCC)

Richard Finn, MD;Olatunji Alese, MD;Daneng Li, MD;Anthony El-Khoueiry, MD;Masatoshi Kudo, MD, PhD;Steven Chan, MD

October 7th 2024

Panelists discuss the current landscape of first-line treatment for unresectable hepatocellular carcinoma, highlighting key options and decision-making factors.